Year All20242023202220212020 May 13, 2024 Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) Read More May 08, 2024 Fractyl Health to Present at BofA Securities 2024 Health Care Conference Read More May 07, 2024 Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 Read More Apr 30, 2024 Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting Read More Apr 02, 2024 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes Read More Apr 01, 2024 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More Apr 01, 2024 Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs Read More Mar 12, 2024 Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity Read More
May 13, 2024 Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
May 07, 2024 Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Apr 30, 2024 Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Apr 02, 2024 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
Apr 01, 2024 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Apr 01, 2024 Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Mar 12, 2024 Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity